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To evaluate demographics of survival in patients with  gastroesophageal cancer so that it 
informs nursing practice.  
Method  
Data on 2215 patients diagnosed with gastroesophageal cancer who presented to a specialist 
referral centre between the years 2000 and 2011 were extracted from a Public Health 
repository. Survival time was calculated and analysed against clinical and lifestyle factors to 
reveal whether they had an impact on survival outcomes.  
Results  
Over 60% of patients had died within the first year, 39% of these died within the first 6 
months. Survival outcomes reduce with advancing age, and in those patients who present as 
'emergency' cases. One quarter of patients were seen by a GP, but were not referred urgently 
through the two week wait system, to specialist care.  
Thus, gastroesophageal cancer patients need specific and appropriate treatment options, 
including earlier referrals to palliative care provision. There is also a need for cancer specific 
education and information at community and clinical levels.  
Conclusions  
The globally applied one and five-year statistics applied to cancer survival studies do not 
adequately capture rates of early demise with gastroesophageal cancer. This study presents a 
novel approach to statistical analysis, based on patient derived data. It identifies factors 
linked to earlier deaths. However, rather than a focus on early presentation and diagnosis 
(which are essential) - it also reveals a significant need to consider early referrals for 













palliative care and nursing interventions to alleviate pain and suffering in patients with poor 
prognosis. 













Graphical Abstract – challenging the 1 year survival statistic in Gastroesophageal cancer  
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This paper proposes a new vision for a more cancer-specific focus on treatment, diagnosis 
and care. There are qualitative differences when palliative care is offered as adjunct to 
oncology services. Palliative care offers patients more information on treatment processes 
and prognosis, the aim is to assist patient and carer coping strategies, and to develop 
advanced care planning directives (Thomas et al, 2019). Palliative care is complementary to 
oncological interventions, it offers family centred care to optimize quality of life, through the 
anticipation, prevention and alleviation of suffering – it meets intellectual, emotional, 
spiritual needs to offer autonomy, access to information and informed choice (Dahlin, 2013). 
Patients should receive dedicated, interdisciplinary palliative support as early as possible in 
the disease process (Ferell et al, 2017).  Furthermore, knowing the trajectory and survival in 
certain cancers can guide healthcare delivery and provide intelligence to assert the most 
appropriate treatment options. For many years, national cancer strategies have focussed on 
encouraging earlier diagnosis and interventions. However, they must also recognise the 
importance of timely referrals to palliation services.  
This paper presents a quantitative analysis of N2215 patients to challenge the commonly 
applied 1-year and 5-year survival outcome measures to cancer statistics. Gastroesophageal 
cancer (GOC), or oesophagogastric cancer, is malignancy of the gastroesophageal junction 
and upper oesophagus. Global trends show a significant rise, and as the 8th most common 
cancer diagnosis, it remains relatively overlooked in current literature (World Cancer 
Research Fund, 2018, Malhotra, 2017). Survival is dependent on surgical removal of the 
tumour (Whitehead et al, 2018, Altorki & Harrison, 2017). In GOC, the ‘red flag warning’ 
physiological symptoms are not always evident until there is major tumour infiltration, so 
survival outcomes remain poor (NCIN, 2018, Thrift et al, 2012). This means many GOC 
patients present too late for curative options, despite National Cancer Campaigns’ to expedite 















referrals and streamline routes to diagnosis (Ellis-Brookes et al, 2012, NCIN, 2016). During 
the first year after surgery, GOC tumours commonly re-present and metastases are found in 
over 80% of patients (Altorki & Harrison, 2017, Whitehead et al, 2018). This means the 
journey from detection and symptoms is multi-faceted for GOC patients.  
Survival outcomes in GOC are influenced by patients’ demographic profiles. The mean age at 
diagnosis is 70 years (SD +/- 20), meaning patients frequently die from age related conditions 
(Coupland et al, 2012). This cancer is also linked with lifestyle factors (smoking, obesity and 
alcohol ingestion) which also bring associated comorbidities. (CRUK, 2017, Parkin, 2010).  
Despite this, GOC tends to be amalgamated with other cancers for research studies. 
Frequently merged with head and neck, gastric and gastrointestinal tract cancers, survival 
outcomes specific to GOC are not always easy to separate from these other cancer groups. 
This is important to note, because different people with different cancers require different 
approaches to care and interventions. Thus, the requirement to evaluate cancer specific data 
and align care options to the patient demographics, is paramount.  
Therefore, this research evaluates the demography of survival in patients with GOC.  The 
sole purpose is to adequately profile a cancer so that it informs intervention strategies (such 
as interdisciplinary palliative care) – to improve quality of life, alleviate pain and suffering 
and bring family centred care to those patients with a poorer prognosis.  
Methods  
A retrospective cohort analysis of every patient referred to a specialist UK cancer centre by 6 
National Health Service sites and multiple primary care referral centres between the years 
2000 to 2011 (N2215).  
Statistical analysis  















Data were retrieved from the United Kingdom, National Cancer Public Health England 
(PHE) datasets. PHE provide information from hospital episode statistics and cancer registry 
to 95% CI accuracy and are accessible through the Office of Data Release, subject to 
National Health Service Ethics Approval and Confidentiality Advisory Group assurance of 
Information Governance and Data Protection conformity (NCIN 2016).  
Date of histological confirmation to date of death was calculated to reveal mean survival in 
days. Tukeys Hinges quartiles were applied to group survival outwith the usual 1-year 
statistic, so groups reflected actual mortality.  
Linear correlations for continuous variables (such as advancing age) were assessed through 
pearsons product moment correlation coefficient. Between group differences were analysed 
through parametric and nonparametric tests and these included: Kruskal Wallis for groups 
exceeding 2, ANNOVA where there was homogeneity and t-distribution was analysed for 
dichotomous variables (Gender). Cox Proportional survival analysis was undertaken to reveal 
survival functions against morphology. Cohen’s (1988) guidelines for effect sizes were 
applied where d=0.2 represents a 'small' effect size, 0.5 represents a 'medium' effect size and 
0.8 a 'large' effect size.  
To reveal the demographic elements of survival with GOC, three groups were developed. 
Group 1 captured the full cohort (N2215) who presented between January 2000 and June 
2011. This was useful to identify age ranges, socioeconomic status, calculate days survival 
and morphology of the cancer. Group 2 captured a sub-cohort (patients presenting after 2006 
with recorded routes to diagnosis) – to evaluate whether routes to diagnosis impacted on 
survival outcomes (N1097). Group 3 related to all patients diagnosed 2000 to 2011 with full 
TNM staging data (N121) to confirm whether advanced stage is a predictor of early demise.  















Socioeconomic data were taken from recorded IMD status at the time of diagnosis. Variables 
such as age, gender, and tumour morphology were taken as recorded in the PHE dataset. 
Routes to diagnosis were taken from the pre-determined cancer outcomes metrics (NCIN, 
2016).   
This research is a part of a larger study into spatiality of gastroesophageal cancer survival. 
The larger study used data captured between 2000 and 2013, (N2785) however, for purposes 
of a 5-year cut point and survival analytics, this paper is based on presentations between 2000 
and 2011. Ethics approval was granted by NHS (IRAS ID 161434), and the host University 
ethics committee.  
Results  
Demographics, survival and mechanisms of presentation  
A total 2215 (living) patients presented to a regional referral centre and had histologically 
confirmed GOC between 2000 and 2011. Table 1 identifies age, gender IMD status and 
tumour morphology for all patients. The average age at presentation was 70 (SD11) and male 
female divide 70:30%. There was an increase in diagnoses for males between ages 65-74.  
71% of the male cohort presented with adenocarcinoma (ADC), whereas females were 
diagnosed with ADC and squamous cell carcinoma (SCC) (43% and 47% respectively). 
In the full cohort, 867 (39%) patients died within the first six months, and a further 471 
(21%) after the initial 6 months, but within the first year. Over 60% of the total cohort died 
on or before 1-year following diagnosis. A further 617 (28%) patients survived between 1 
and 5 years. Only 260 (12%) patients remained alive at 5 years after the date of histological 
confirmation. The median survival time (in days) was 264 days (Tukeys Hinges quartiles 
ranged 107 lower – to 634 higher day survival range) (See figure 1).  
This proposed 6 month statistic captures the following groups:  















1) Deaths within 6 months of presentation to cancer specialist services n = 867 (39%) 
(Patients presenting with aggressive tumours, or too late for curative treatment) 
2) Deaths up to 1 year n = 471 (21%) (>6 month presentations, may have had surgical 
interventions, but with limited curative options. 
3) Death 1-5-years n = 617 (28%) Patients who have received surgical intervention of a 
curative or palliative nature 
4) Survival > 5-years n = 260 (12%) Considered as patients who have survived, or are in 
remission of the disease process. 
Data on routes to diagnosis have been recorded in the UK cancer statistics since January 
2006. Table 2 uses a 6 month survival cut point in addition to the 1 year survival, for analysis 
against the general ‘routes to presentation’. It illustrates the general patient journey from 
diagnosis to death. Emergency and two week wait routes were common to those who died 
within the first 6 months. There was a stochastic dominance in the emergency presentation 
group, linking emergency presentation with reduced days survival  (5, n = 1097) = 112, p = 
< 0.05. Those alive after 6 months, but who died before 1 year more commonly presented 
through the ‘2-week wait’ referrals. Over a quarter of this cohort (54 patients out of a total 
222), presented to their GP but their symptoms were not considered appropriate for referrals 
through the 2-week wait system. Survivors and those dying between 1 and 5 years tended to 
present via 2-week wait, or through a non-urgent GP referral.  
Lifestyles and demography.  
Demographic variables were explored against survival, thus allowing isolation of the effects 
of treatments, from the effects of other variables. It was used a priori as other variables, such 
as advancing age, date of presentation and poor initial vital status have been shown to have 
an impact on long term survival.  















Preliminary exploration of data exploring relationships between advancing age and survival 
revealed that there were no violations of the assumptions of normality, linearity and 
homoscedasticity. A statistically significant difference in survival days between the 6 
different age groups was identified (gp 1 N= 36: 0-44 yrs, gp 2 N=174: 45-54 yrs, gp 3 
N=457: 55-64 yrs, gp 4 N=707: 65-74 yrs, gp 5 N=621: 75-84 yrs, gp 6 N=220: 85plus) X2 
(5, N=2215) = 20.1 p=0.001. There was a small negative correlation between age and 
survival, (r = -.28, n2215, p<0.01) meaning advancing age decreases survival outcomes, but 
that only 7% of variance in survival can be explained by advancing age (r2 = .729). Patients 
over the age of 65 experienced fewer days alive after their GOC diagnosis (Md=350 N=1374) 
when compared to those under 65 (Md171 N=841) U 39661p=0.001. z= -12.4 r= 0.3.  
There was no significant difference in survival scores between males (mean 524 days) and 
females (469 days) (t (2215) = 2.07, P 0. 04 (two tailed)). The magnitude of the differences in 
means (95% ci 3.0-106.5) was very small (eta squared = 0.001).  
Survival time has increased over the duration of this cohort timescale  (11, N = 2215) = 
31.54, p = 0.01. Patients presenting after the year 2006 had improved survival outcomes, 
when compared with those presenting before 2006. The pre 2006 group displayed worse 
survival in days (Median 234, n 1116), whereas the post 2006 group exhibited a small 
improvement in survival outcomes (Median N = 310, n 1099 U = 535907, Z = -5.1, P = 0.01, 
r = 0.1). Mean survival outcomes were greater in patients who were offered surgical 
intervention (p = 0.005).  
There was a very small, but statistically significant difference in survival days between lower 
socioeconomic groups and higher (IMD 1&2 versus IMD 4&5) (P<0.005 eta squared = 0.02) 
though these findings must be considered against the lower effect size. Analysis revealed 















statistically significant differences in survival days between groups.  (4, n = 2215) = 38.6, p 
= 0.05, suggesting an association between lower deprivation scores and poor survival. 
The main GOC morphology in the survival cohort (N2215) was adenocarcinoma (ADC) with 
papillary and squamous cell (SCC) second. Cancers labelled as ‘other’ included neoplasms 
and cystic/mucinous morphology and these were diagnosed in 258 cases (Table 3).  
Mean days survival after diagnosis in squamous cell carcinoma was 485, Adenocarcinoma 
was 543 and all other cancers was 368 days. For SCC, 61% of the cohort died within a year 
and 11 % survived to 5 year. 57% of ADC sufferers died within a year of diagnosis and 13% 
survived over 5 year.  
There was a statistically significant difference in days survival  post diagnosis between the 
three morphology groups (SCC n = 620, ADC N=1337, Other N= 258). X2 (2, N=2215) =16, 
p=.005. The ADC groups had a higher median score in days survived (MD291) than the other 
two groups, with values of MD 245 and 212. Cox proportional survival anaysis revealed 
survival functions decrease with time in all 3 groups (CI 95 %, P=<0.05).  
Discussion  
The aim of this study was to evaluate the demographics of survival in gastroesophageal 
cancer, to reveal elements of the care trajectory which can inform appropriate interventions. 
By offering analysis of this large group of patients with gastroesophageal cancer, it was 
evident that a significant percentage would have benefitted from an holistic care package and 
early intervention palliative care and support.  
Several significant factors were identified in this research. Namely – that the 1 year survival 
statistic does not articulate GOC, that patients with advanced symptoms have worse 
outcomes, that over ¼ of patients presented to their GP – but were not referred urgently for 















GOC screening, and that increasing age, emergency presentation and socioeconomic 
deprivation is linked to impaired survival.  
Figure 1 illustrated the significant proportion of patients who had died within 6 months of 
their diagnosis. They would ordinarily be missed and merged into the 1 year ‘commonly 
applied’ survival statistic. Thus, a generic ‘1 year’ statistic does not fully capture the extent of 
mortality across the total timeframe. This intelligence can be used to drive initiatives to 
instigate palliative care, to reduce suffering and to deliver the appropriate care to those 
patients and their families who were most at need.  
Findings illustrated that use of the 1 year survival statistic missed a full 39% of patients dying 
before 6 months. A further 21% died before the 1-year survival statistic. A biologically 
plausible explanation for this would be to suggest those patients who died within the first 6 
months, either had other comorbidities, presented at a very late stage, or had extremely 
aggressive tumours.  
However, this information is crucial to inform healthcare. Those 39% of patients dying 
within 6 months would be more appropriate for alternative interventions. For example, early 
diagnosis strategies are not necessarily going to have an effect on these patient groups. 
Instead, the focus should be on palliative care, alleviation of pain, further research into 
practices which alleviate symptoms exacerbated by this cancer (such as dietetics and 
nutrition, pain management, palliative care options, counselling). This study’s findings are 
commensurate with existing literature (CRUK, 2017, Coupland et al., 2012). However, this is 
the first study to generate survival data and identify the need for a 6 month cut point. By 
applying gold standard ‘interval measures’ for cancer research (Weller et al, 2012), this study 
proposes new parameters to support gastroesophageal cancer survival analysis - one which 
represents death rates at 6 months.   
















For those patients with records of ‘routes to diagnosis’ (n = 1097), the two week wait was the 
most common route (42% of the cohort). This national cancer strategy, to expedite care and 
treatment has been effective in increasing diagnoses of GOC (NICE, 2015, Meecham et al., 
2012, Vedstead & Olessen, 2011, Hamilton et al., 2015). However, this study identified that 
25% of the total cohort did receive a GP referral, but this was not considered urgent enough 
for the two week wait system. This is important information for those working in primary 
care, as it highlights the need for education and training in detection of GOC symptoms.  
Unsurprisingly, this study linked advancing age with reduced survival. This may be 
biologically attributed to the ageing process, which frequently manifests with comorbidities 
and frailty (Chang et al, 2018, Hogan, 2018, Hirani, 2017). The mean age of diagnosed 
patients was 70 years, so the skew to an older population in gastroesophageal cancer means 
the cohorts studied will be subject to the many confounding variables of ageing. The fact that 
male diagnoses increased between the ages 65-74 would suggest that nurses working with 
patients over 50, could consider offering patients information of that signs, symptoms and 
nature of the disease.  
Modifiable risk factors such as smoking, diet, physical activity and increased BMI are more 
commonly identified in deprived groups, and are attributed to reduced survival outcomes in 
several studies on cancer (Coupland et al., 2012, Hastert et al., 2016, Danzig et al., 2014, 
Hagedoorn, 2016 Worsley, Wang & Hunter, 2011). This study showed a small but significant 
correlation between socioeconomic deprivation and poor survival and this finding is 
supported by other studies (Exarcachou et al, 2018, Arnold, 2012, Abnet et al, 2018, Xie & 
Leggegren, 2018).  
Strengths and weaknesses of this study.  















Although this study was based on referrals made to only one UK Cancer regional referral 
centre this did constitute a population catchment area of an estimated 1682000 and covers a 
number of healthcare institutions. Furthermore, although these data represent one 
geographical region, the demography of this region is diverse providing a good example of 
other healthcare areas in the UK.   
A major aspect of the rigour of this study lies in the reliance of English cancer registry data, 
which is highly regarded for its quality and completeness (95%CI CRUK, 2017). The 
incomplete data on TNM staging in this database is common in gastroesophageal cancer 
studies (Mahar et al, 2018, Anandavadivelan et al, 2018, Islami, 2018, Neal, 2015).  
Conclusion and recommendations for further research 
This paper identified some factors which are crucial to informing care at the end of life. 
Working with gastroesophageal cancer patients means providing the most relevant treatment 
to meet their needs. This research identified a significant skewed survival trajectory, which 
supported early integrated palliative care strategies. Nurses, as significant providers of 
palliative care, can use these statistics to ensure they are involved in the systematic planning 
of care for these patients.  
However, as with any form of change in systems and healthcare delivery, this has financial 
and resource implications. Further study would be required to review how earlier palliative 
nursing care interventions will impact resources. Longer term care delivery options may 
improve individualised care outcomes – but the evidence remains unclear on costs 
(Salamanca-Balen et al, 2018). They may prevent hospital admissions and length of stay, but 
the evidence remains uncertain on cost-effectiveness.  
This paper offers an information source for nurses to prepare patients (and families) for the 
disease trajectory and prognosis. Cancer care, treatment and support is an interdisciplinary 















process, but nurses are key to this process. They must use information and evidence 
effectively, supporting an interdisciplinary team to provide the best possible care for GOC 
patients.   
The overall message is that the globally ageing population means gastroesophageal cancer 
incidence will potentially increase. Therefore, more resources will be required to deliver the 
most appropriate care for patients. Survival analysis should reflect the survival trajectory, and 
missing a significant proportion of patients who die within the first 6 months after GOC 
diagnosis is unacceptable. This information offers a key driver to inform palliative and 
alternate care strategies – to engage interdisciplinary led palliative care which addresses the 
actual needs of patients (and their families) who have this cancer.  
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Table 1 demographic data gastroesophageal cancer cohort (N2215) 
 Total Gender 
Male Female 
Age Grouped  <44  36 (2%) 26 10 
45-55  174 (7%) 127 47 
56-64  457 (21%) 355 102 
65-74  707 (32%) 523 184 
75-84  621 (28%) 386 235 
85+  220 (10%) 98 122 
Socioeconomic  
Status (IMD 10)  
Least deprived 351 (16%) 251 100 
Not deprived 505 (23%) 336 169 
Mid 467 (21%) 317 150 
Deprived 391 (18%) 268 123 
Most deprived 501 (23%) 343 158 
Morphology  Neoplasm (not spec)  13 (.5%) 9 4 
 Epithelial neoplasm  128 (6%) 84 44 
 Papilliary and SCC  620 (28%) 280 340 
 Adenocarcinoma  1337 (60%) 1050 287 
 Cystic and mucinous  100 (5%) 77 23 
 Mixed neoplasms  17 (1%) 15 2 
 













Table 2 – Mechanisms of presentation against survival  
TOTAL     
1097 
 















134  81  23  11  126  4  
Deaths up 
to 1 year  
28  54 18 8 113 1 
Death 1-5-
years  
38  91 35 11 158 11 
Survival > 
5-years  
12  41 
 












359 days 349 days 593 days  
 













Table 3 – Site and Morphology of cancer in the new survival groups 
TOTAL     COHORT (N 
2215) 







SCC ADC Other 
Deaths within 6 months of 
presentation to cancer 
specialist services n = 867 
(39%) (Patients presenting 
with aggressive tumours, 





















Deaths up to 1 year n = 
471 (21%)  
(>6 month presentations, 
may have had surgical 
interventions, but with 




















Death 1-5-years n = 617 
(28%) Patients who have 
received surgical 
intervention of a curative 




















Survival > 5-years n = 
260 (12%) Considered as 
patients who have 
survived, or are in 



































Figure 1 – proposed survival groups  
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Use and application of the 1-year survival statistic in gastroesophageal cancer misses a 
significant group of patients and does not reflect the pattern of early deaths in this cancer.  
We need to adequately profile cancer so that it informs intervention strategies which focus, 
not merely on encouraging earlier diagnosis, but on treating those with later staged diagnosis, 
most effectively, thus alleviating pain and suffering in patients with poorer prognosis.  
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